ReviewJournal of molecular neuroscience : MN2014
Protein-based biomarkers in cerebrospinal fluid and blood for Alzheimer's disease.
Review in Journal of molecular neuroscience : MN, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Advanced Overview of Biomarkers and Techniques for Early Diagnosis of Alzheimer's Disease.Cellular and molecular neurobiology · 2023Review
- The Association of Blood-Based Inflammatory Factors IL-1β, TGF-β and CRP with Cognitive Function in Alzheimer's Disease and Mild Cognitive Impairment.Psychiatry investigation · 2021Article
- Mechanism involved in insulin resistance via accumulation of β-amyloid and neurofibrillary tangles: link between type 2 diabetes and Alzheimer's disease.Drug design, development and therapy · 2018Review
- Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [Frontiers in aging neuroscience · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is a common neurodegenerative disease. Although early diagnosis of AD is challenging, identification and treatment at the preclinical stage is critical for preventing the severe and irreversible damage to neurons. Thus, during the last few decades, many researchers have sought efficient biomarkers for early diagnosis of AD, monitoring disease progression, and gauging responses to therapies. Recently, various molecular markers have been investigated in blood, plasma, cerebrospinal fluid, and other body fluids. This review summarizes the results of some recent studies that searched for biomarkers of AD in cerebrospinal fluid (CSF) and blood.
Indexed as
Identifiers
24961342What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.